Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 281 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Humatrope Clear all
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 2, 2026, 6:31 PM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 2, 2026, 6:31 PM EDT
Recruiting Early Phase 1 Interventional

Growth Hormone for the Treatment of Gastroparesis

NCT06803589
View directory record Official record
Conditions
Gastroparesis
Interventions
Growth Hormone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 2, 2026, 6:31 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial

NCT04375657
View directory record Official record
Conditions
Epigenetic Aging, Immunosenescence
Interventions
TRIIM Treatment, Active Control
Combination Product
Lead sponsor
Intervene Immune, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism

NCT05187377
View directory record Official record
Conditions
Phelan-McDermid Syndrome, Autism Spectrum Disorder (ASD)
Interventions
Growth Hormone, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 2, 2026, 6:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

NCT05690386
View directory record Official record
Conditions
Turner Syndrome
Interventions
Lonapegsomatropin, Somatropin
Biological · Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 10 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients

NCT00244075
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplement, recombinant human growth hormone (rcGH), exercise
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced Sep 2, 2026, 6:31 PM EDT
Not listed No phase listed Observational

Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight

NCT00120497
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

NCT03882034
View directory record Official record
Conditions
Pituitary Disease
Interventions
Pegvisomant
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure

NCT00791843
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Growth hormone releasing hormone/ placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 2, 2026, 6:31 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

NCT03878446
View directory record Official record
Conditions
Short Stature Children Born Small for Gestational Age (SGA)
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Trial of Growth Hormone Therapy in Pediatric Crohn's Disease

NCT00109473
View directory record Official record
Conditions
Crohn's Disease
Interventions
growth hormone, cortecosteroid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 3 Interventional

Effect of Growth Hormone in Children With Growth Hormone Deficiency

NCT00262249
View directory record Official record
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children, Growth Disorder, Idiopathic Short Stature
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
40
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 6:31 PM EDT
Withdrawn Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

NCT00003514
View directory record Official record
Conditions
Merkel Cell Carcinoma, Islet Cell Carcinoma, Neuroendocrine Carcinoma, Pituitary Tumor
Interventions
antineoplaston A10, antineoplaston AS2-1, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

NCT01412424
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

NCT02122380
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 2, 2026, 6:31 PM EDT
Recruiting Phase 3 Interventional

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT07221851
View directory record Official record
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

NCT00001860
View directory record Official record
Conditions
Acromegaly, Pituitary Neoplasm
Interventions
Sandostatin LAR Depot versus transsphenoidal surgery
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 2, 2026, 6:31 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supplementation Trial on Arginine With Metabolic Profiling

NCT03409380
View directory record Official record
Conditions
Protein, Amino Acid, Arginine
Interventions
Arginine Drink, Plain Drink
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 2, 2026, 6:31 PM EDT
Completed No phase listed Observational

Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

NCT01302652
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 6:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

NCT00871455
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Baclofen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 2, 2026, 6:31 PM EDT
Terminated No phase listed Observational

Constructing an Insulin-Like Growth Factor-based Prediction Model

NCT00263445
View directory record Official record
Conditions
Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
3 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 2, 2026, 6:31 PM EDT